For those that have followed me over the last few decades in the industry you know my passion for ensuring we find ways to democratize access to best possible care for all patients. When we started Paradigm it was with this mission at the forefront - how do we entirely reimagine the clinical development ecosystem - not in an incremental way - but in a more punctuated equilibrium moment for the industry. A bold vision to create equitable access to clinical trials and best possible care for all providers and their patients - with the byproduct being faster and more efficient drug development. At Paradigm, we’ve spent the past year working at full speed to create health equity across all patient populations by building a new model for clinical trials. Today we announced that Bristol Myers Squibb, one of the leading pharmaceutical companies in the world, equally realizes the challenges with today’s status quo and wants to collaborate to address it. As we’ve put together this relationship, I’ve been struck by how everyone, across both companies, has reached a breaking point with the complexity of timelines to get new drugs to market and the fact that in that process, patients from the most important demographics and communities are often left out. We are thrilled to have a visionary partner like Bristol Myers Squibb share this goal with us! I know this will be the first of many such relationships as other biopharma companies realize how much faster and more effectively we can bring new, important drugs to market when everyone has the opportunity to participate in research. #BristolMyersSquibb #BMS #Paradigm #equitableaccess
At Paradigm, we're creating a new patient-centric model for clinical trials. When more patients have the option to participate, we can achieve better care and help bring new treatments to market faster. Today we’re announcing a new collaboration with Bristol Myers Squibb: to build a new end-to-end model for clinical trials, starting in oncology. Our two organizations share a commitment to bring access to clinical trials to underserved populations and reduce the burden of trials on patients and providers – which will speed both recruitment and results. Read more in our press release here --->https://lnkd.in/g4kDd8zC
Elena Viboch
11mo
BMS and Paradigm have the potential to acceleration patient access to breakthrough medicines and we couldn’t be more excited!
Milind Kamkolkar
11mo
so happy to see this come through Kent Thoelke 🏳️🌈 When two awesome companies come together on a transformational mission, only good things can happen across healthcare :) Congrats, my friend and to my dear colleagues at Paradigm & Bristol Myers Squibb
Stephen Klasko
11mo
Kent, this is perfect! Congratulations ... and yes, I believe this kind of acceleration will make drug development more equitable. This is what it takes.
Wendy Taylor
10mo
Congrats and cheers to health equity 🎉 Thanks for paving the way 🙏
Bilal Zuberi
11mo
Indeed a terrific milestone on an important new journey! We are all beneficiaries of your experience in this space.
Sarah Dolman
11mo
Wow - impressive to already have a major partner in this space less than a year after launching from stealth! Way to go Ken & team!
Udichi Lahiri
11mo
Congratulations, Kent Thoelke 🏳️🌈 and the Paradigm team, on the partnership with Bristol Myers Squibb! Your mission to democratize access to clinical trials and create health equity is both timely and essential. Can't wait to see the ripple effects of this partnership in accelerating drug development and expanding patient access.
Laney Preheim
10mo
Fabulous! Can’t wait to see how this unfolds.
Very excited to work together!